182 related articles for article (PubMed ID: 22283189)
1. Characterization of cancer stem-like cells in chordoma.
Aydemir E; Bayrak OF; Sahin F; Atalay B; Kose GT; Ozen M; Sevli S; Dalan AB; Yalvac ME; Dogruluk T; Türe U
J Neurosurg; 2012 Apr; 116(4):810-20. PubMed ID: 22283189
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
3. Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma.
Gulluoglu S; Sahin M; Tuysuz EC; Yaltirik CK; Kuskucu A; Ozkan F; Sahin F; Ture U; Bayrak OF
Oncol Res; 2017 Aug; 25(7):1177-1188. PubMed ID: 28247842
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Alholle A; Brini AT; Bauer J; Gharanei S; Niada S; Slater A; Gentle D; Maher ER; Jeys L; Grimer R; Sumathi VP; Latif F
Epigenetics; 2015; 10(3):213-20. PubMed ID: 25621392
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas.
Bayrak OF; Gulluoglu S; Aydemir E; Ture U; Acar H; Atalay B; Demir Z; Sevli S; Creighton CJ; Ittmann M; Sahin F; Ozen M
J Neurooncol; 2013 Nov; 115(2):143-51. PubMed ID: 23912551
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
7. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.
Karikari IO; Gilchrist CL; Jing L; Alcorta DA; Chen J; Richardson WJ; Gabr MA; Bell RD; Kelley MJ; Bagley CA; Setton LA
J Neurosurg Spine; 2014 Sep; 21(3):386-93. PubMed ID: 24905390
[TBL] [Abstract][Full Text] [Related]
9. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.
Vujovic S; Henderson S; Presneau N; Odell E; Jacques TS; Tirabosco R; Boshoff C; Flanagan AM
J Pathol; 2006 Jun; 209(2):157-65. PubMed ID: 16538613
[TBL] [Abstract][Full Text] [Related]
10. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
Ostroumov E; Hunter CJ
Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of a primary human chordoma xenograft model.
Siu IM; Salmasi V; Orr BA; Zhao Q; Binder ZA; Tran C; Ishii M; Riggins GJ; Hann CL; Gallia GL
J Neurosurg; 2012 Apr; 116(4):801-9. PubMed ID: 22283186
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract][Full Text] [Related]
13. [Novel molecular aspects of chordomas].
Scheil-Bertram S
Pathologe; 2014 Nov; 35 Suppl 2():237-41. PubMed ID: 25394972
[TBL] [Abstract][Full Text] [Related]
14. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue.
Tirabosco R; Mangham DC; Rosenberg AE; Vujovic S; Bousdras K; Pizzolitto S; De Maglio G; den Bakker MA; Di Francesco L; Kalil RK; Athanasou NA; O'Donnell P; McCarthy EF; Flanagan AM
Am J Surg Pathol; 2008 Apr; 32(4):572-80. PubMed ID: 18301055
[TBL] [Abstract][Full Text] [Related]
15. Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development.
Gottschalk D; Fehn M; Patt S; Saeger W; Kirchner T; Aigner T
Am J Pathol; 2001 May; 158(5):1571-8. PubMed ID: 11337353
[TBL] [Abstract][Full Text] [Related]
16. Chordoma: the entity.
Yakkioui Y; van Overbeeke JJ; Santegoeds R; van Engeland M; Temel Y
Biochim Biophys Acta; 2014 Dec; 1846(2):655-69. PubMed ID: 25193090
[TBL] [Abstract][Full Text] [Related]
17. From notochord formation to hereditary chordoma: the many roles of Brachyury.
Nibu Y; José-Edwards DS; Di Gregorio A
Biomed Res Int; 2013; 2013():826435. PubMed ID: 23662285
[TBL] [Abstract][Full Text] [Related]
18. HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Jäger D; Barth TFE; Brüderlein S; Scheuerle A; Rinner B; von Witzleben A; Lechel A; Meyer P; Mayer-Steinacker R; Baer AV; Schultheiss M; Wirtz CR; Möller P; Mellert K
Sci Rep; 2017 May; 7(1):2032. PubMed ID: 28515451
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
20. The effects of chemotherapeutic agents on differentiated chordoma cells.
Bayrak OF; Aydemir E; Gulluoglu S; Sahin F; Sevli S; Yalvac ME; Acar H; Ozen M
J Neurosurg Spine; 2011 Dec; 15(6):620-4. PubMed ID: 21905773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
